Literature DB >> 14711438

Polypoidal choroidal vasculopathy.

Antonio P Ciardella1, Irene M Donsoff, Sheau J Huang, Danielle L Costa, Lawrence A Yannuzzi.   

Abstract

Polypoidal choroidal vasculopathy was first described as a peculiar hemorrhagic disorder of the macula, characterized by recurrent sub-retinal and sub-retinal pigment epithelium bleeding in middle aged black women. The use of indocyanine green angiography and subsequently of optical coherent tomography has widened our ability to study and understand the pathophysiology of this disorder. The primary abnormality involves the choroidal circulation, and the characteristic lesion is an inner choroidal vascular network of vessels ending in an aneurysmal bulge or outward projection, visible clinically as a reddish orange, spheroid, polyp-like structure. We have also recognized that individuals of African-American and Asian descents are more at risk for developing polypoidal choroidal vasculopathy as the disorder seems to preferentially affect pigmented individuals. However, it has been shown that while that still holds true, patients of other racial backgrounds may be afflicted. Particularly, polypoidal choroidal vasculopathy has been found to be present in about 8-13% of white patients with clinical appearance of exudative age-related macular degeneration. Polypoidal choroidal vasculopathy has also been reported in Irish, French, German, and Italian patients. The natural course of the disease often follows a remitting-relapsing course, and clinically, it is associated with chronic, multiple, recurrent serosanguineous detachments of the retinal pigment epithelium and neurosensory retina with long-term preservation of good vision. Photodynamic treatment appears to be a promising alternative to conventional laser therapy, for the treatment of polypoidal choroidal vasculopathy. In conclusion, polypoidal choroidal vasculopathy seems to be a distinct clinical entity that should be differentiated from other types of choroidal neovascularization associated with age-related macular degeneration and other known choroidal degenerative, inflammatory, and ischemic disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711438     DOI: 10.1016/j.survophthal.2003.10.007

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  105 in total

1.  Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2011-09-29       Impact factor: 2.447

2.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

4.  Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography.

Authors:  Fumi Gomi; Miki Sawa; Keiichi Mitarai; Motokazu Tsujikawa; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-09       Impact factor: 3.117

5.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

6.  A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients.

Authors:  Xiao-Li Chen; Qin-Rui Hu; Yu-Jing Bai; Yu Deng; Hai-Wei Wang; Shan Liu; Yin-Lin Wang; Yan-Kun Yue
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

7.  Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea.

Authors:  Young Gun Park; Seungbum Kang; Young Jung Roh
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

8.  Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis.

Authors:  Long-Hui Han; Li-Fei Yuan; Xu Liang; Xin Jia; Ming-Lian Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

9.  Nasal and independent polypoidal lesions in polypoidal choroidal vasculopathy.

Authors:  Akiko Okubo; Noriko Abematsu; Taiji Sakamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-11       Impact factor: 3.117

10.  COL8A1 rs13095226 polymorphism shows no association with neovascular age-related macular degeneration or polypoidal choroidal vasculopathy in Chinese subjects.

Authors:  Yang Yu; Lvzhen Huang; Bin Wang; Chunfang Zhang; Yujing Bai; Xiaoxin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.